Experiment 1116950
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Empty organism |
| Citation | HUTCHEON,AW: PALMER,JBD: PRATT,MA: CLARK,RA:. (1983). PHASE II EVALUATION OF VINDESINE IN NON-SMALL CELL BRONCHOGENIC CARCINOMA.. 67(11) |
| Amount utilized | |
| Compound isolated | |
| Disease | A PHASE II STUDY INVOLVING 48 PATIENTS WITH NON-SMALL CELL BRONCHOGENIC CARCINOMA. DOSING WAS WEEKLY AS A BOLUS INJECTION THROUGH A FREE-FLOWING IV LINE FOR SIX WEEKS. PATIENTS RESPONDING CONTINUED TO RECEIVED THE DRUG EVERY TWO WEEKS. THERE WERE NO COMPLETE RESPONSES. TWO PATIENTS WITH EPIDERMOID CARCINOMA, FIVE WITH ADENOCARCINOMA AND TWO WITH LARGE CELL UNDIFFERENTIATED CARCINOMA ACHIEVED A PARTIAL RESPONSE. IN ALL RESPONDING PATIENTS, OBJECTIVE TUMOR REGRESSION OCCURED WITHIN 4 WEEKS OF TREATMENT INITIATION. SITES OF RESPONSE WERE LUNG(7 PATIENTS), LYMPH NODES(THREE), PLEURA(ONE) AND LIVER(ONE). THREE OF THE NINE PATIENTS RESPONDED IN MORE THAN ONE SITE. PRIOR TREATMENT WITH RADIOGRAPHY DID NOT AFFECT THE RESPONSE RATE. TOXICITY SEEN WAS SIMILAR TO THAT OF PREVIOUS REPORTS. NEUROTOXIC EFFECTS WERE MOST OFTEN MANIFESTED BY NONPROGRESSIVE PARESTHESIAS WHICH WERE CUMULATIVE ON THE WEEKLY SCHEDULE BUT DID NOT PROGRESS ON THE MAINTENANCE SCHEDULE. LEUKOPENIA WAS MILD AND DOSE-LIMITING IN ONLY 15% OF PATIENTS RECEIVING THE WEEKLY REGIMEN. |
| Dose amount | 3.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | SQ M BODY SURFACE |
| Dose expression | DOSE |
| Gender | GIVEN TO BOTH SEXES |